Drugs / QL1701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05629949 | Apr 2020 → Dec 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL1701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05629949 ↗ |
| Route | Intravenous | “Participants received intravenous infusion of QL1701 with docetaxel.” NCT05629949 ↗ |